Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Neuren Pharmaceuticals Ltd Receives Orphan Drug Designation From FDA For NNZ-2566 In Fragile X Syndrome


Tuesday, 29 Oct 2013 11:26pm EDT 

Neuren Pharmaceuticals Ltd announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NNZ-2566 for treatment of Fragile X Syndrome. 

Related Company News

Company Quote

0.089
-0.0020 -2.20%
28 Aug 2015